pioneering diagnostic products based on its Prognosis Determinants™ Platform. Prognosis Determinants™ are functionally validated genetic elements at the core of cancer progression across many major cancer types. Based on pioneering research in melanoma by Dr. Lynda Chin at the Dana-Farber Cancer Institute and Harvard Medical School, the Prognosis Determinants™ were first discovered as functionally active drivers of metastasis that confer poor outcome. Prognosis Determinants™ have been shown to be relevant to a broad spectrum of different tumors and can stratify patients according to their overall and metastasis-free survival.